UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 176

Sortiert nach

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

Cancer letters, 2020-03, Vol.473, p.186-197

2020

Volltextzugriff (PDF)

Abstract P242: Preclinical efficacy landscape of the pan-CLK/DYRK inhibitor Cirtuvivint (SM08502)

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P242-P242

2021

Volltextzugriff (PDF)

Abstract P250: Evaluation of systemic pan-CLK/DYRK inhibition on organ function and tissue self-renewal

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P250-P250

2021

Volltextzugriff (PDF)

Daily Walking among Commuters: A Cross-Sectional Study of Associations with Residential, Work, and Regional Accessibility in Melbourne, Australia (2012-2014)

Environmental health perspectives, 2019-09, Vol.127 (9), p.97004

2019

Volltextzugriff (PDF)

Abstract 6401: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6401-6401

2020

Volltextzugriff (PDF)

Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5691-5691

2020

Volltextzugriff (PDF)

Abstract A09: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models

Clinical cancer research, 2020-07, Vol.26 (13_Supplement), p.A09-A09

2020

Volltextzugriff (PDF)

Abstract C09: Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models

Cancer research (Chicago, Ill.), 2019-12, Vol.79 (24_Supplement), p.C09-C09

2019

Volltextzugriff (PDF)

Abstract A02: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models

Cancer research (Chicago, Ill.), 2019-12, Vol.79 (24_Supplement), p.A02-A02

2019

Volltextzugriff (PDF)

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

Blood, 2019-11, Vol.134 (Supplement_1), p.3913-3913

2019

Volltextzugriff (PDF)

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models

Blood, 2019-11, Vol.134 (Supplement_1), p.1377-1377

2019

Volltextzugriff (PDF)

Between Dimensions

Antigonish review, 2015-06 (182), p.104

Stewart, Josh (Canadian educator)

2015

Volltextzugriff (PDF)

What Was Left Behind

Antigonish review, 2014-03 (177), p.121

Stewart, Josh (Canadian educator)

2014

Volltextzugriff (PDF)

Abstract 5019: Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5019-5019

2023

Volltextzugriff (PDF)

Examining the Relationship of Work-Family Conflict and Turnover Intentions of Oregon CTE Teachers

Career and technical education research, 2019-10, Vol.44 (2), p.114

2019

Volltextzugriff (PDF)

Evaluation of the Efficacy of a Onetime Injectable Dexamethasone Administered Orally in the Pediatric Emergency Department for Asthma Exacerbation

The journal of pediatric pharmacology and therapeutics, 2017-09, Vol.22 (5), p.326-331

2017

Volltextzugriff (PDF)

Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3928-3928

2022

Volltextzugriff (PDF)

Exploring Leadership Development Through Community‐Based Experiences

Journal of leadership studies (Hoboken, N.J.), 2017-12, Vol.10 (4), p.6-16

2017

Volltextzugriff (PDF)

Abstract 2745: INK128, a TORC1/2 kinase inhibitor, enhances the efficacy of cytotoxic therapies in endometrial tumor models

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2745-2745

2012

Volltextzugriff (PDF)

Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3753-3753

2012

Volltextzugriff (PDF)

That’s not in my position description: A discourse analysis of SBAE migratory context

Journal of agricultural education, 2023-09, Vol.64 (3), p.203-224

2023

Volltextzugriff (PDF)

Here Are the Keys, Go Teach: How Alternatively Certified Agriculture Teachers Learn to Be Agriculture Teachers

Journal of agricultural education, 2023-06, Vol.64 (2), p.98-115

2023

Volltextzugriff (PDF)

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A171-A171

2011

Volltextzugriff (PDF)

Abstract A172: INK128, an orally active TORC1/2 kinase inhibitor, displays enhanced efficacy when combined with cytotoxic agents

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A172-A172

2011

Volltextzugriff (PDF)

Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.4501-4501

2011

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(161)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(176)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(70)
Humans
(43)
Female
(29)
Male
(25)
Adult
(19)
Middle Aged
(16)
Infectious Diseases
(15)
Patients
(13)
Teachers
(12)
Tropical Medicine
(12)
Physical Sciences
(11)
Risk Factors
(11)
Animals
(10)
Aged
(9)
Agricultural Education
(9)
Covid-19
(8)
Hospitals
(8)
Infections
(8)
Public, Environmental & Occupational Health
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

Abstract P242: Preclinical efficacy landscape of the pan-CLK/DYRK inhibitor Cirtuvivint (SM08502)

Abstract P250: Evaluation of systemic pan-CLK/DYRK inhibition on organ function and tissue self-renewal

Daily Walking among Commuters: A Cross-Sectional Study of Associations with Residential, Work, and Regional Accessibility in Melbourne, Australia (2012-2014)

Abstract 6401: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models

Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models

Abstract A09: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models

Abstract C09: Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models

Abstract A02: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models

Between Dimensions

What Was Left Behind

Abstract 5019: Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies

Examining the Relationship of Work-Family Conflict and Turnover Intentions of Oregon CTE Teachers

Evaluation of the Efficacy of a Onetime Injectable Dexamethasone Administered Orally in the Pediatric Emergency Department for Asthma Exacerbation

Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models

Exploring Leadership Development Through Community‐Based Experiences

Abstract 2745: INK128, a TORC1/2 kinase inhibitor, enhances the efficacy of cytotoxic therapies in endometrial tumor models

Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer

That’s not in my position description: A discourse analysis of SBAE migratory context

Here Are the Keys, Go Teach: How Alternatively Certified Agriculture Teachers Learn to Be Agriculture Teachers

Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations

Abstract A172: INK128, an orally active TORC1/2 kinase inhibitor, displays enhanced efficacy when combined with cytotoxic agents

Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer

Suchergebnisse filtern